Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform

Key Takeaway: Johnson & Johnson has announced its acquisition of Firefly Bio, Inc., aiming to enhance its oncology pipeline. This strategic move focuses on integrating Firefly's novel degrader antibody conjugate platform, which is expected to provide innovative treatment options for cancer patients. The acquisition reflects JNJ's commitment to advancing its biopharmaceutical capabilities.